198 related articles for article (PubMed ID: 33871687)
1. Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome.
Basel D; Mosheva M; Maeder J; Schneider M; Shani S; Weinberger R; Eliez S; Gothelf D
Eur Child Adolesc Psychiatry; 2022 Sep; 31(9):1367-1375. PubMed ID: 33871687
[TBL] [Abstract][Full Text] [Related]
2. Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.
Gothelf D; Law AJ; Frisch A; Chen J; Zarchi O; Michaelovsky E; Ren-Patterson R; Lipska BK; Carmel M; Kolachana B; Weizman A; Weinberger DR
Biol Psychiatry; 2014 Mar; 75(5):406-13. PubMed ID: 23992923
[TBL] [Abstract][Full Text] [Related]
3. Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome.
Niarchou M; Chawner SJRA; Fiksinski A; Vorstman JAS; Maeder J; Schneider M; Eliez S; Armando M; Pontillo M; Vicari S; McDonald-McGinn DM; Emanuel BS; Zackai EH; Bearden CE; Shashi V; Hooper SR; Owen MJ; Gur RE; Wray NR; van den Bree MBM; Thapar A;
Schizophr Res; 2019 Feb; 204():320-325. PubMed ID: 30093352
[TBL] [Abstract][Full Text] [Related]
4. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome.
Monks S; Niarchou M; Davies AR; Walters JT; Williams N; Owen MJ; van den Bree MB; Murphy KC
Schizophr Res; 2014 Mar; 153(1-3):231-6. PubMed ID: 24534796
[TBL] [Abstract][Full Text] [Related]
5. Attention Deficit Hyperactivity Disorder Symptoms and Psychosis in 22q11.2 Deletion Syndrome.
Niarchou M; Calkins ME; Moore TM; Tang SX; McDonald-McGinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
Schizophr Bull; 2018 Jun; 44(4):824-833. PubMed ID: 29040797
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review.
Mosheva M; Korotkin L; Gur RE; Weizman A; Gothelf D
Eur Child Adolesc Psychiatry; 2020 Aug; 29(8):1035-1048. PubMed ID: 30949827
[TBL] [Abstract][Full Text] [Related]
7. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial.
Green T; Steingart L; Frisch A; Zarchi O; Weizman A; Gothelf D
J Neural Transm (Vienna); 2012 Nov; 119(11):1417-23. PubMed ID: 22678699
[TBL] [Abstract][Full Text] [Related]
8. Association of COMT and PRODH gene variants with intelligence quotient (IQ) and executive functions in 22q11.2DS subjects.
Carmel M; Zarchi O; Michaelovsky E; Frisch A; Patya M; Green T; Gothelf D; Weizman A
J Psychiatr Res; 2014 Sep; 56():28-35. PubMed ID: 24853458
[TBL] [Abstract][Full Text] [Related]
9. Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS.
Michaelovsky E; Gothelf D; Korostishevsky M; Frisch A; Burg M; Carmel M; Steinberg T; Inbar D; Apter A; Weizman A
Int J Neuropsychopharmacol; 2008 May; 11(3):351-63. PubMed ID: 17949513
[TBL] [Abstract][Full Text] [Related]
10. Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study.
Mekori-Domachevsky E; Guri Y; Yi J; Weisman O; Calkins ME; Tang SX; Gross R; McDonald-McGinn DM; Emanuel BS; Zackai EH; Zalsman G; Weizman A; Gur RC; Gur RE; Gothelf D
Schizophr Res; 2017 Oct; 188():42-49. PubMed ID: 28041919
[TBL] [Abstract][Full Text] [Related]
11. The clinical presentation of attention deficit-hyperactivity disorder (ADHD) in children with 22q11.2 deletion syndrome.
Niarchou M; Martin J; Thapar A; Owen MJ; van den Bree MB
Am J Med Genet B Neuropsychiatr Genet; 2015 Dec; 168(8):730-8. PubMed ID: 26400629
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and tolerability of pharmacotherapy for psychosis in 22q11.2 Deletion Syndrome: A systematic review.
Tanham M; Chen R; Warren N; Heussler H; Scott JG
Aust N Z J Psychiatry; 2024 May; 58(5):393-403. PubMed ID: 38383990
[TBL] [Abstract][Full Text] [Related]
13. The clinical course of individuals with 22q11.2 deletion syndrome converting to psychotic disorders: a long-term retrospective follow-up.
Kulikova K; Schneider M; McDonald McGinn DM; Dar S; Taler M; Schwartz-Lifshitz M; Eliez S; Gur RE; Gothelf D
Eur Child Adolesc Psychiatry; 2024 Jun; ():. PubMed ID: 38834873
[TBL] [Abstract][Full Text] [Related]
14. Deep psychophysiological phenotyping of adolescents and adults with 22q11.2 deletion syndrome: a multilevel approach to defining core disease processes.
Parker DA; Cubells JF; Imes SL; Ruban GA; Henshey BT; Massa NM; Walker EF; Duncan EJ; Ousley OY
BMC Psychiatry; 2023 Jun; 23(1):425. PubMed ID: 37312091
[TBL] [Abstract][Full Text] [Related]
15. Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome - Clinical and scientific implications.
Mekori-Domachevsky E; Taler M; Weinberger R; Guri Y; Dar S; Shani S; Dekel I; Weizman A; Gothelf D
Schizophr Res; 2021 May; 231():164-169. PubMed ID: 33866261
[TBL] [Abstract][Full Text] [Related]
16. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.
Mekori-Domachevsky E; Taler M; Shoenfeld Y; Gurevich M; Sonis P; Weisman O; Weizman A; Gothelf D
J Clin Psychiatry; 2017; 78(9):e1219-e1225. PubMed ID: 29141125
[TBL] [Abstract][Full Text] [Related]
17. Education and employment trajectories from childhood to adulthood in individuals with 22q11.2 deletion syndrome.
Mosheva M; Pouillard V; Fishman Y; Dubourg L; Sofrin-Frumer D; Serur Y; Weizman A; Eliez S; Gothelf D; Schneider M
Eur Child Adolesc Psychiatry; 2019 Jan; 28(1):31-42. PubMed ID: 29934817
[TBL] [Abstract][Full Text] [Related]
18. The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome.
Dori N; Green T; Weizman A; Gothelf D
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):83-90. PubMed ID: 26131914
[TBL] [Abstract][Full Text] [Related]
19. Developmental changes in multivariate neuroanatomical patterns that predict risk for psychosis in 22q11.2 deletion syndrome.
Gothelf D; Hoeft F; Ueno T; Sugiura L; Lee AD; Thompson P; Reiss AL
J Psychiatr Res; 2011 Mar; 45(3):322-31. PubMed ID: 20817203
[TBL] [Abstract][Full Text] [Related]
20. Selective Effects of Methylphenidate on Attention and Inhibition in 22q11.2 Deletion Syndrome: Results From a Clinical Trial.
Maeder J; Mancini V; Sandini C; Journal F; Schneider M; Kliegel M; Eliez S
Int J Neuropsychopharmacol; 2022 Mar; 25(3):215-225. PubMed ID: 34453525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
